New pill for platinum-resistant ovarian cancer with cyclin E1
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian cancer called high-grade serous (the most common type).
- Your cancer stopped responding to platinum chemotherapy or came back within 6 months of your last platinum treatment.
- You have had between 1 and 4 different cancer treatments (including the first one) after your diagnosis.
- You have already tried bevacizumab (Avastin), unless it wasn't safe for you.
- If your tumor has a certain protein (FRα), you must have tried the drug mirvetuximab soravtansine, unless it wasn't safe for you.
- You are willing to have a biopsy (tissue sample) taken before starting the study drug, or you have a sample from the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
This Phase 2 study tests an immunotherapy approach for women whose high-grade serous ovarian cancer came back within 6 months of platinum chemotherapy. It may help shrink tumors and improve control of the disease, but you’ll need tumor biopsies and lab/heart/lung checks to join.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.